The findings highlight genetic NDDs as genome-informed yet exposure-sensitive disorders and several external factors that both represent markers of epilepsy severity and may support early, genetically informed seizure management and careful stewardship of treatment exposures.
Abstract
Objective
The mechanistic effects of genetic variants underlying genetic neurodevelopmental disorders (NDDs) are widely studied, but the contribution of external factors remains largely unexplored.
Methods
In this cross-sectional study using the Simons Searchlight population dataset, we examined caregiver-reported environmental exposures and functional outcomes from 970 individuals with (67%) and without (33%) epilepsy across 93 NDDs. The primary outcome was adaptive function (Vineland-3) at last follow-up, with quality of life (Quality of Life Inventory-Disability) and autism symptoms (Social Communication Questionnaire-Lifetime) as secondary analyses.
Results
Compared to individuals with NDDs without epilepsy, individuals with epilepsy had lower adaptive function (p < .001). On multivariable regression analysis, we found positive associations between socioeconomic factors and quality of life (parents' highest educational status: β = .014, p = .013; annual household income: β = .007, p = .021) and negative associations between treatment-related factors and adaptive function (treatment with sodium channel blockers: β = -.087, p = 2.44 × 10-5; hospitalizations: β = -.055, p = 3.65 × 10-7). These associations were mediated by epilepsy duration, etiology, and polytherapy. Results were consistent across sensitivity analyses but were not observed in individuals without epilepsy, suggesting epilepsy-specific effects. Together, environmental exposures explained more variance in developmental outcomes than genetic etiology alone (additional R2 = 19.6%, p = .003). Importantly, the additional variance explained by environmental exposures was different across genes, ranging from ~15% (SCN2A, SLC6A1) to >30% (16p11.2 deletion), suggesting gene-specific vulnerability. Overall, ~60% of variance in developmental outcomes remained unexplained, motivating further studies on genome and exposome influences.
Significance
Our findings highlight genetic NDDs as genome-informed yet exposure-sensitive disorders. We found several external factors that both represent markers of epilepsy severity and may support early, genetically informed seizure management and careful stewardship of treatment exposures. Prospective, controlled studies are needed to disentangle the developmental effects of the underlying disease from treatment-related factors.
These prediction models demonstrate the feasibility of early prognostication in KCNQ2-RD and support future prospective external validation and enable more accurate individualised counselling by integrating clinical and genetic information readily available at time of genetic diagnosis.
E. Van Boxstael, C. Millevert, M. Hairabedian et al.· medRxiv· 0 citations
AIM
Childhood-onset Type 1 diabetes (T1D) is associated with neurodevelopmental conditions (NDCs). We examined whether this association extends to relatives and assessed phenotypic, genetic, and environmental correlations between T1D and NDCs.
METHODS
Using Swedish registers, we identified 4 066 634 individuals born 1973-2015 and linked them to siblings and cousins; 23 212 (0.57%) had T1D before 18 years. Logistic regression estimated odds of receiving a diagnosis of any and each of the examined NDCs among individuals with T1D and their relatives. Bivariate quantitative genetic models estimated phenotypic, additive genetic, shared environmental, and non-shared environmental correlations. Analyses were conducted in April 2025.
RESULTS
NDCs were more prevalent among individuals with T1D than in those without (10.3% vs. 6.4%). T1D was associated with higher odds of receiving a diagnosis of any NDCs (OR 1.43; 95% CI 1.37-1.49). Full siblings also had higher odds (OR 1.12; 95% CI 1.06-1.18), whereas no significant associations were observed among other relatives. Cross-trait phenotypic correlations were small (0.06-0.08).
CONCLUSION
Individuals with childhood-onset T1D and their full siblings had higher odds of recorded NDC diagnoses. Shared familial factors appeared to contribute only modestly, while differential ascertainment and family-level consequences of T1D may also play a role. These findings support access to neurodevelopmental expertise in paediatric diabetes services.
Shengxin Liu, G. Machado, Irzam Hardiansyah et al.· Acta paediatrica· 0 citations
AIM
To investigate correlates of quality of life (QoL) in individuals with neurodevelopmental genetic conditions (NGCs), such as PTEN hamartoma tumor syndrome (PHTS), SYNGAP1-related conditions, and Malan syndrome, and their families.
METHOD
Caregivers of 201 individuals with NGCs (50.2% male; 43.3% with PHTS) filled out a battery of online questionnaires. Two five-step hierarchical regressions were used to identify key correlates of both caregiver-reported family QoL (FQoL) and health-related QoL (HRQoL).
RESULTS
In the final step of the regression model predicting FQoL, greater social communication and interaction, higher speech level, fewer challenging behaviors, and greater executive functioning skills were related to higher FQoL. With regard to HRQoL, male sex, decreased mood dysregulation, and fewer sleep problems (more specifically, less restless sleep and difficulty waking) were related to greater HRQoL.
INTERPRETATION
These findings highlight the complex interplay of factors affecting distinct aspects of QoL, underscoring the need for interventions that go beyond focusing on features of autism by incorporating a focus on broader clinical, developmental, and cognitive profiles.
Rachel K. Schuck, E. Baker, Kaitlynn M. P. Baiden et al.· Developmental Medicine & Chi...· 1 citation
BACKGROUND AND OBJECTIVES
Evidence remains inconclusive on whether paternal valproate exposure during spermatogenesis is associated with adverse offspring outcomes, with findings lacking beyond Nordic countries. This study aimed to assess the risks of neurodevelopmental disorders (NDDs) and congenital malformations in offspring attributable to paternal exposure to valproate and other antiseizure medications (ASMs) during sperm development.
METHODS
This nationwide birth cohort study used data from the Taiwan National Health Insurance Research Database, including individuals born 2001-2016 who were followed up through 2021. Paternal exposure to valproate or other ASMs was defined during the time of spermatogenesis (3 months before conception). Exposure discordant sibling sets were identified for sibling-comparison analysis to control for shared genetic and lifestyle factors. NDDs-including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), intellectual disability (ID), and tic disorder-and congenital malformations were defined by outpatient and inpatient medical record(s). Relative risks were estimated through Cox proportional hazards models for NDDs (hazard ratios [HRs]) and logistic regression for congenital malformations (odds ratios [ORs]).
RESULTS
In the population cohort of 2,583,503 individuals, 1,701 were exposed to paternal use of valproate and 548 exposure-discordant sibling sets were available for sibling-comparison analysis. In population-based analyses, paternal valproate exposure was not associated with the risk of NDDs (HRs = 0.86 [95% CI 0.61-1.22] for ASD, 1.02 [0.88-1.18] for ADHD, 0.80 [0.53-1.20] for tic disorders, and 0.81 [0.55-1.19] for ID) or congenital malformations (OR = 1.07 [0.83-1.37]) in offspring. These null effects persisted when restricting analyses to children of fathers with epilepsy to control for confounding by indication, and when the sibling-comparison analysis was conducted. For other ASMs, a few associations appeared at nominal significance, but none remained in sibling-comparison analyses.
DISCUSSION
In this large population-based study in Asia, we found no increased risk of NDDs in offspring following paternal exposure to valproate or other ASMs. These findings may contribute to ongoing debates about the management of valproate in men of reproductive age, although additional evidence is needed before drawing conclusions about changes to current practice.
Y. A. Feng, Mei-Chen Lin, Ching-Hsuan Tseng et al.· Neurology· 0 citations
Although several associations reached nominal significance, none remained significant after correction for multiple comparisons and the precision of the estimates was constrained by the available imaging GWAS sample size, uncertainty in SNP-heritability estimates, and the large number of regional comparisons.
Mengman Wei, Qian Peng· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.